MedTrace Logo

Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

NCT00439166 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-19

No results posted yet for this study

Summary

This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect of those treatments.

Conditions

Interventions

DRUG

doxycycline

capsule, 100 mg, b.i.d., daily for 1 year

DRUG

rifampicin

capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)

DRUG

Placebo matched to doxycycline

Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months

DRUG

Placebo matched to Rifampin

Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • William Molloy, MB, FRCPC · McMaster University

  • Tricia KW Woo, MD, FRCPC · McMaster University

  • David D Cowan, MD, FRCPC · McMaster University

  • Brandon M Kucher, PhD · McMaster University

  • Alwin Cunje, MD, PhD · University of Ottawa

  • Tim I Standish, MA · McMaster University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2010-04-30
Completion
2010-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439166 on ClinicalTrials.gov